Last reviewed · How we verify
IRL757
At a glance
| Generic name | IRL757 |
|---|---|
| Sponsor | Integrative Research Laboratories AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy (PHASE1, PHASE2)
- Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers (PHASE1)
- First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IRL757 CI brief — competitive landscape report
- IRL757 updates RSS · CI watch RSS
- Integrative Research Laboratories AB portfolio CI